Drug Trial Radar · NCT03070782
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
Last checked: Nov 19, 2026Latest source record: Oct 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
286
Actual
Start
Mar 7, 2017
Primary completion
Jul 26, 2018
Study completion Nov 13, 2018
Sponsor
- Lead sponsor
- Akcea TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Ionis Pharmaceuticals, Inc.
- First posted
- Mar 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lipoprotein(a) \[Lp(a)\] levels in participants with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).
Conditions
- Elevated Lipoprotein(a)
- Cardiovascular Disease
Interventions
ISIS 681257Drug
ISIS 681257 solution for SC injection.
PlaceboDrug
Sterile normal saline (0.9% NaCl)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Fasting Lipoprotein A [Lp(a)] at the Primary Analysis Time PointTime frame: Baseline and Month 6 (Week 25 for Cohorts A, B and C and Week 27 for Cohorts D and E)
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 16 weeks post treatment period (up to approximately 1.3 years)
- Number of Participants With TEAEs by Maximum SeverityTime frame: Up to 16 weeks post treatment period (up to approximately 1.3 years)
- Number of Participants With TEAEs Leading to Study DiscontinuationTime frame: Up to 16 weeks post treatment period (up to approximately 1.3 years)
Locations
32 sites in 5 countries. Site status is shown where the registry gives one.
Clinical Site
Cottonwood, Arizona
Clinical Site
Huntington Beach, California
Clinical Site
La Jolla, California
Clinical Site
Los Angeles, California
Clinical Site
Stanford, California
Clinical Site
Colorado Springs, Colorado
Clinical Site
Boca Raton, Florida
Clinical Site
Jacksonville, Florida
Clinical Site
Kansas City, Kansas
Clinical Site
Baltimore, Maryland
Clinical Site
Boston, Massachusetts
Clinical Site
Cooperstown, New York
Clinical Site
New York, New York
Clinical Site
New York, New York
Clinical Site
Cleveland, Ohio
Clinical Site
Portland, Oregon
Clinical Site
Lancaster, Pennsylvania
Clinical Site
Philadelphia, Pennsylvania
Clinical Site
Providence, Rhode Island
Clinical Site
Houston, Texas
Clinical Site
Falls Church, Virginia
Clinical Site
Milwaukee, Wisconsin
Clinical Site
Ottawa, Canada
Clinical Site
Chicoutimi, Quebec, Canada
Clinical Site
Montreal, Quebec, Canada
Clinical Site
Montreal, Quebec, Canada
Clinical Site
Québec, Quebec, Canada
Clinical Site
Herlev, Denmark
Clinical Site
Viborg, Denmark
Clinical Site
Berlin, Germany
Clinical Site
Cologne, Germany
Clinical Site
Amsterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.